WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY) Read More 1st December 2023
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED ACCESS PROTOCOL FOR IMETELSTAT Read More 17th July 2023
WEP CLINICAL HAS PARTNERED WITH THERATECHNOLOGIES TO LAUNCH A NAMED PATIENT PROGRAM FOR EGRIFTA SV® Read More 13th July 2023
WEP CLINICAL HAS PARTNERED WITH PHARMING GROUP TO SUPPLY LENIOLISIB POST-FDA APPROVAL THROUGH A POST-APPROVAL NAMED PATIENT PROGRAM Read More 20th June 2023
WEP CLINICAL PARTNERS WITH SOLASIA PHARMA K.K. TO LAUNCH DARVIAS NAMED PATIENT PROGRAM Read More 20th March 2023
WEP CLINICAL PARTNERS WITH Y-MABS THERAPEUTICS TO PROVIDE DANYELZA THROUGH A NAMED PATIENT ACCESS PROGRAM IN EUROPE Read More 16th February 2023
WEP CLINICAL HAS PARTNERED WITH TAIMED BIOLOGICS TO LAUNCH A TROGARZO NAMED PATIENT PROGRAM Read More 6th February 2023
WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY)1st December 2023/Read More2023
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED ACCESS PROTOCOL FOR IMETELSTAT17th July 2023/Read More2023
WEP CLINICAL HAS PARTNERED WITH THERATECHNOLOGIES TO LAUNCH A NAMED PATIENT PROGRAM FOR EGRIFTA SV®13th July 2023/Read More2023
WEP CLINICAL HAS PARTNERED WITH PHARMING GROUP TO SUPPLY LENIOLISIB POST-FDA APPROVAL THROUGH A POST-APPROVAL NAMED PATIENT PROGRAM20th June 2023/Read More2023
WEP CLINICAL PARTNERS WITH SOLASIA PHARMA K.K. TO LAUNCH DARVIAS NAMED PATIENT PROGRAM20th March 2023/Read More2023
WEP CLINICAL PARTNERS WITH Y-MABS THERAPEUTICS TO PROVIDE DANYELZA THROUGH A NAMED PATIENT ACCESS PROGRAM IN EUROPE16th February 2023/Read More2023
WEP CLINICAL HAS PARTNERED WITH TAIMED BIOLOGICS TO LAUNCH A TROGARZO NAMED PATIENT PROGRAM6th February 2023/Read More2023
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH PHARMING GROUP FOR EXPANDED ACCESS PROGRAM FOR LENIOLISIB8th June 2022/Read More2022
WEP CLINICAL PARTNERS WITH SELLAS LIFE SCIENCES GROUP TO LAUNCH EXPANDED ACCESS PROGRAM FOR GALINPEPIMUT-S4th May 2022/Read More2022
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS FOR NAMED PATIENT USE PROGRAM FOR UPLIZNA14th January 2022/Read More2022
WEP CLINICAL PARTNERS WITH KINIKSA TO LAUNCH ARCALYST NAMED PATIENT PROGRAM17th August 2021/Read More2021
WEP CLINICAL EXECUTES MASTER SERVICES AGREEMENT WITH MEDLAB TO BRING NANABIS™ AND NANOCBD™ TO PATIENTS IN UK AND EUROPE VIA…19th July 2021/Read More2021
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH HORIZON THERAPEUTICS PLC TO LAUNCH NAMED PATIENT USE PROGRAM FOR TEPEZZA® (TEPROTUMUMAB-TRBW)18th May 2021/Read More2021
WEP CLINICAL EXPANDS AVAILABILITY OF XENLETA® (LEFAMULIN) NAMED PATIENT PROGRAM IN PARTNERSHIP WITH NABRIVA THERAPEUTICS25th March 2021/Read More2021
WEP CLINICAL EXTENDS PARTNERSHIP WITH BTG SPECIALTY PHARMACEUTICALS BY GAINING WORLDWIDE (EX-US) DISTRIBUTION RIGHTS FOR DIGIFAB®1st March 2021/Read More2021
WEP CLINICAL PARTNERS WITH US BIOTECH COMPANY FOR THE NAMED PATIENT SUPPLY OF CANCER PRODUCT IN EX-US COUNTRIES24th August 2020/Read More2020
WEP CLINICAL PARTNERS WITH BTG SPECIALTY PHARMACEUTICALS FOR EUROPEAN SUPPLY OF VORAXAZE®1st July 2020/Read More2020
WEP CLINICAL PARTNERS WITH NABRIVA THERAPEUTICS FOR THE NAMED PATIENT SUPPLY OF XENLETA® (LEFAMULIN)30th June 2020/Read More2020
WEP CLINICAL JOINS WITH WREN HEALTHCARE TO PROVIDE HOME HEALTHCARE SERVICES25th June 2020/Read More2020
WEP CLINICAL PARTNERS WITH MYLAN TO PROVIDE PRODUCT FOR HIGHLY DRUG-RESISTANT TUBERCULOSIS1st June 2020/Read More2020
WEP CLINICAL AND WELLSTAT THERAPEUTICS CORPORATION ENTER INTO NEW PARTNERSHIP FOR THE NAMED PATIENT SUPPLY OF VISTOGARD® (URIDINE TRIACETATE)23rd January 2020/Read More2020
WEP CLINICAL LAUNCHES NITISINONE MDK IN THE EU ON BEHALF OF MENDELIKABS INC.28th November 2019/Read More2019
WEP Clinical and MendeliKABS Inc. enter exclusive Named Patient distribution agreement for MDK-Nitisinone17th February 2017/Read More2017
